Photocure Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dan Schneider

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	6yrs
Proprietà del CEO	0.4%
Durata media del management	6yrs
Durata media del Consiglio di amministrazione	1.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Dan Schneider

6yrs

Mandato

Mr. Daniel Schneider, also known as Dan, joined Photocure ASA since November 2018 and has been President & CEO of PhotoCure ASA since November 1, 2018. He has been Vice President of Sales at Pernix Sleep,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Daniel Schneider	President & CEO	6yrs	Nessun dato	0.37% € 421.6k
Erik Dahl	Chief Financial Officer	12.3yrs	Nessun dato	0.12% € 138.5k
David Moskowitz	Head of Investor Relations	no data	Nessun dato	Nessun dato
Anja Gossens-von der Heidt	Head of Global Human Resources	no data	Nessun dato	Nessun dato
Anders Neijber	Chief Medical Officer of Global Medical Affairs	2.2yrs	Nessun dato	Nessun dato
Tolv Hillestad	Group Controller	no data	Nessun dato	Nessun dato

6.0yrs

Durata media

Gestione esperta: Il team dirigenziale di PHS è esperto e expertise (durata media dell'incarico 6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Johanna Holldack	Independent Director	7.6yrs	Nessun dato	Nessun dato
Neal Shore	Independent Director	no data	Nessun dato	Nessun dato
Dylan Hallerberg	Independent Chairman	1.8yrs	Nessun dato	0.55% € 634.4k
Ghizlane Tagmouti	Director	less than a year	Nessun dato	Nessun dato
Malene Brandborg	Independent Director	no data	Nessun dato	Nessun dato

1.8yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PHS non è considerato esperto (durata media del mandato 1.8 anni), il che suggerisce un nuovo consiglio.

Photocure Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Photocure ASA Announces Board Appointments

Less than half of directors are independent

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Recent updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.81 loss in 1Q 2022)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

New 90-day high: €10.40

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

New 90-day high: €9.02

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media